Table 1.
Characteristics of patients with COVID-19 in hospitalization and critical care.
| No hospitalization | Hospitalization | P value | Critical care | P value | |
|---|---|---|---|---|---|
| Number of patients, n (%) | n = 27,018 | n = 1075 | n = 336 | ||
| Age, mean (SD), years | 50.2 (17.3) | 65.5 (15.2) | < 0.001 | 65.5 (13.6) | 0.9423 |
| Sex (male/female) | 11,238/15,780 | 564/511 | < 0.001 | 206/130 | 0.004 |
| T2D, n (%) | 4094 (15) | 351 (33) | < 0.001 | 123 (37) | 0.18 |
| HbA1c < 7%, n (%) | 2569 (9) | 43 (4) | 0.309 | 17 (5) | 0.656 |
| HbA1c ≥ 7%, n (%) | 852 (3) | 34 (3) | 0.309 | 11 (3) | 0.656 |
| Alpha-glucosidase inhibitor, n (%) | 2 (0) | 0 (0) | 0.778 | 0 (0) | 1 |
| DPP4 inhibitor, n (%) | 4 (0) | 0 (0) | 0.69 | 0 (0) | 1 |
| Incretin mimetic, n (%) | 495 (2) | 16 (1) | 0.408 | 9 (3) | 0.149 |
| Insulin, n (%) | 13 (0) | 0 (0) | 0.472 | 0 (0) | 1 |
| Meglitinide, n (%) | 4 (2) | 0 (0) | 0.69 | 0 (0) | 1 |
| Metformin, n (%) | 644 (2) | 19 (2) | 0.133 | 5 (1) | 0.814 |
| SGLT2 inhibitor, n (%) | 379 (1) | 10 (1) | 0.194 | 4 (1) | 0.674 |
| Sulfonylurea, n (%) | 392 (1) | 13 (1) | 0.508 | 4 (1) | 0.978 |
| Thiazolidinedione, n (%) | 89 (0) | 3 (0) | 0.777 | 1 (0) | 0.955 |
| Fatty liver, n (%) | 421 (2) | 8 (1) | 0.033 | 1 (0) | 0.369 |
| BMI mean (SD), kg/m2 | 33.4 (8.7) | 35.5 (10.4) | < 0.001 | 36.4 (10.3) | < 0.001 |
| BMI < 30 kg/m2, n (%) | 6810 (25) | 149 (14) | < 0.001 | 32 (10) | < 0.001 |
| BMI ≥ 30 kg/m2, n (%) | 10,938 (40) | 356 (33) | < 0.001 | 108 (32) | < 0.001 |
Hospitalization (n = 1075) included critical care patients (n = 336). P value compared with the not-hospitalized group.